前收市價 | 10.17 |
開市 | 10.10 |
買盤 | 9.91 x 3500 |
賣出價 | 10.01 x 1300 |
今日波幅 | 9.94 - 10.28 |
52 週波幅 | 4.54 - 16.75 |
成交量 | |
平均成交量 | 7,176,291 |
市值 | 2.339B |
Beta 值 (5 年,每月) | 0.83 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.58 |
業績公佈日 | 2024年5月06日 - 2024年5月10日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 13.00 |
The 2020 COVID-19 outbreak caused massive human suffering, job loss, disruption and financial market panic. From the Feb. 19, 2020, high to the stock market bottom of the COVID panic in March 2020, the S&P 500 declined about 34%. World Health Organization Director General Tedros Ghebreyesus is sounding the alarm, warning that "the world is not prepared for a pandemic." His argument that it's a "matter of when, not if" a new pandemic will strike sounds similar to billionaire Bill Gates's recent p
The company just made a provocative move in one of its collaborations.
The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime. Curing these diseases would be invaluable. The likelihood of that happening is something one can only dream of today. Yet based on research from Wood’s Ark Invest, the companies pursuing these treatments could see their enterprise value race higher by a 28% compounded annual growth rate. That me